Research and Practice in Thrombosis and Haemostasis最新文献

{"title":"Comparative safety of oral anticoagulants in severe renal impairment","authors":"Rosalind Byrne , Lara N. Roberts","doi":"10.1016/j.rpth.2026.103449","DOIUrl":"10.1016/j.rpth.2026.103449","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"10 3","pages":"Article 103449"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147712384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemophilia B gene therapy: a NAb–solute barrier overcome by adeno-associated virus serotype 5","authors":"Radoslaw Kaczmarek","doi":"10.1016/j.rpth.2026.103428","DOIUrl":"10.1016/j.rpth.2026.103428","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"10 3","pages":"Article 103428"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147712386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic strategies in intracerebral hemorrhage: from hematoma stabilization to alleviating secondary brain injury","authors":"Pei-Feng Hsieh ,&nbsp;Yen-Bo Liu ,&nbsp;Charlotte Cordonnier ,&nbsp;Hsin-Hsi Tsai","doi":"10.1016/j.rpth.2026.103423","DOIUrl":"10.1016/j.rpth.2026.103423","url":null,"abstract":"<div><div>A state-of-the-art lecture titled, “New Treatment Targets in Intracerebral Hemorrhage,” was presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in 2025. Intracerebral hemorrhage remains one of the most devastating forms of stroke, with high rates of mortality and long-term disability. Unlike ischemic stroke, treatment options remain limited, but advances in pathophysiological understanding and clinical trials have expanded the range of potential therapeutic strategies. This review synthesizes current evidence across 3 major interdependent domains. First, hematoma stabilization focuses on preventing hematoma expansion through intensive blood pressure control, hemostatic agents, and reversal of antithrombotic therapies, with recent prehospital and care bundle trials demonstrating promise. Second, strategies to reduce hematoma burden and the mass effect include both surgical evacuation and enhancement of endogenous clearance mechanisms. While minimally invasive surgery has shown selective benefits in carefully chosen patients, increasing attention is being directed toward accelerating natural hematoma resolution via microglial and macrophage-mediated phagocytosis, as well as modulating iron toxicity. Third, mitigation of secondary brain injury targets perihematomal edema, oxidative stress, and neuroinflammation. Recent trials of glibenclamide, anti-inflammatory agents, COX-2 inhibitors, and antioxidants have indicated both the challenges and opportunities of modulating secondary injury. Together, these developments represent a transition from therapeutic nihilism toward optimism but emphasize a need for multimodal and time-sensitive interventions. Finally, we summarize relevant new data on this topic presented during the 2025 ISTH Congress.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"10 3","pages":"Article 103423"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147712444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DETECT-VTE: an audit of patients with venous thromboembolism and their characteristics in general practice in the United Kingdom","authors":"Jo Jerrome ,&nbsp;Christopher J. Michaels ,&nbsp;Naman Kochar ,&nbsp;Matthew Fay ,&nbsp;Beverley J. Hunt","doi":"10.1016/j.rpth.2026.103431","DOIUrl":"10.1016/j.rpth.2026.103431","url":null,"abstract":"<div><h3>Background</h3><div>There is a paucity of data informing the incidence and characteristics of patients with venous thromboembolism (VTE) in primary health care.</div></div><div><h3>Objectives</h3><div>The DETECT-VTE clinical audit explored the profile of patients with VTE in general practitioner (GP) practices in the UK.</div></div><div><h3>Methods</h3><div>Data were audited from GP records of 687 adults with deep vein thrombosis (DVT) and/or pulmonary embolism (PE), including their characteristics, health care service presentation locations and visit frequency, symptoms, vital signs, and risk factors with which they presented.</div></div><div><h3>Results</h3><div>VTE (DVT, 49%; PE, 46%; both, 5%) was diagnosed in 180 individuals per 100,000 in the audited population between January and December 2023. VTE diagnosis was mostly initiated at GP practices (46%), with 62% of patients having multiple health care visits in the 8 weeks prior to the initiation of their diagnosis, although reasons for these visits were not captured. Common symptoms were painful and/or swollen legs in patients with DVT and chest pain and breathlessness in patients with PE, although several less common symptoms were observed. Key preidentified VTE risk factors reported in the audit included age ≥ 60 years and obesity, with patients aged ≥60 years frequently also exhibiting obesity, immobility, cancer, recent hospitalization, and previous VTE.</div></div><div><h3>Conclusions</h3><div>The DETECT-VTE study emphasizes the role of GP practices in diagnosing VTE. While VTE diagnosis is typified by constellations of risk factors and symptoms, patient presentations can vary substantially. These findings reinforce the need for VTE vigilance in GP practices.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"10 3","pages":"Article 103431"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147712455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analytical validity of the INNOVANCE Antithrombin assay for the measurement of antithrombin activity at fitusiran clinical decision points","authors":"Christoph Freidel ,&nbsp;Martina Boehm-Weigert ,&nbsp;Christine Dahler ,&nbsp;Marek Demissie ,&nbsp;Hong Wang ,&nbsp;Mingjie Liu ,&nbsp;Shariq Ali ,&nbsp;Ekta Seth Chhabra","doi":"10.1016/j.rpth.2026.103450","DOIUrl":"10.1016/j.rpth.2026.103450","url":null,"abstract":"<div><h3>Background</h3><div>Fitusiran is an antithrombin (AT)-lowering therapy for hemophilia A and B, with dosing individually adjusted to maintain AT activity between 15% and 35%. The therapy, therefore, requires an AT activity assay with high analytical sensitivity and precision, especially at the lower end of the measuring range (≤20%).</div></div><div><h3>Objectives</h3><div>This study evaluated the analytical performance characteristics of the INNOVANCE Antithrombin assay at the low end of the measuring range and assessed equivalence between different analyzers.</div></div><div><h3>Methods</h3><div>Performance data were generated on various analyzers from Siemens Healthineers according to Clinical and Laboratory Standards Institute guidelines, including limit of quantification (LoQ), interferences, and precision. System comparability was evaluated using samples from patients treated with fitusiran.</div></div><div><h3>Results</h3><div>This study demonstrated high precision and reproducibility of results across reagent lots and systems with &lt;10% coefficient of variation at 10% and 15% AT activity on all analyzers, except for the BCS XP system at the 10% AT level, with a repeatability coefficient of variation of 13.94%. Diluted control plasma showed similar precision characteristics to native samples and good recovery of expected AT value. Therapeutics potentially being used by the hemophilia population were demonstrated to not interfere with the assay. LoQ was shown to be ≤8.78% of normal on all analyzers. System comparability was confirmed with correlation coefficients of ≥0.997, slopes between 0.976 and 1.005, and intercepts between 0.5% and 2.1% of normal.</div></div><div><h3>Conclusion</h3><div>The study confirms the INNOVANCE Antithrombin assay can precisely and reliably quantify AT activity at fitusiran clinical decision points and further supports its suitability for clinical management of people on fitusiran prophylaxis.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"10 3","pages":"Article 103450"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147746646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capturing the late complications of venous thromboembolism","authors":"Anette Arbjerg Højen ,&nbsp;Elin Baddeley ,&nbsp;Stine Foged Lindegaard ,&nbsp;Stian Ingemann-Molden ,&nbsp;Frederikus A. Klok","doi":"10.1016/j.rpth.2026.103420","DOIUrl":"10.1016/j.rpth.2026.103420","url":null,"abstract":"<div><div>A state-of-the-art lecture titled “Capturing the late complications of venous thromboembolism: the role of patient-reported outcomes” was presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2025 in Washington, DC. Venous thromboembolism (VTE) is increasingly recognized as a chronic condition with substantial long-term complications that extend beyond recurrence, bleeding, and survival. Many patients with VTE experience persistent pain, dyspnea, fatigue, anxiety, and reduced quality of life. Frequently used terms for clinical sequalae include postthrombotic syndrome and postpulmonary embolism syndrome, the latter of which includes chronic thromboembolic pulmonary hypertension. Despite the impact of these long-term complications, they are rarely addressed systematically in routine daily practice. Patient-reported outcome measures provide a structured framework for capturing these late complications, complementing clinical outcomes and offering unique insights into the patient perspective. This review outlines why late complications should be systematically captured, describes the patient-reported outcome measures commonly used to assess them, and discusses key opportunities and challenges for their integration into clinical practice. Finally, we summarize relevant new data on this topic presented during the 2025 ISTH Congress.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"10 3","pages":"Article 103420"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147712364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global survey of women’s awareness of pregnancy- and postpartum-associated venous thromboembolism (World Thrombosis Day 2025)","authors":"Marcello Di Nisio ,&nbsp;Isabelle Mahé ,&nbsp;Parham Sadeghipour ,&nbsp;John Suviraj ,&nbsp;Anila Rashid ,&nbsp;Ann Marie O’Neill ,&nbsp;Beverley J. Hunt ,&nbsp;Sabrina Hadim ,&nbsp;Fahimeh Ghotbizadeh ,&nbsp;Ettore Porreca ,&nbsp;Helen Okoye ,&nbsp;Marco Liberati ,&nbsp;Jaromir Gumulec ,&nbsp;Saskia Middeldorp ,&nbsp;Cihan Ay ,&nbsp;Cedric Hermans ,&nbsp;Manuel Monreal ,&nbsp;Patricia Casais ,&nbsp;Nicola Potere ,&nbsp;Matteo Candeloro ,&nbsp;Stefano Barco","doi":"10.1016/j.rpth.2026.103421","DOIUrl":"10.1016/j.rpth.2026.103421","url":null,"abstract":"<div><h3>Background</h3><div>Venous thromboembolism (VTE) is a leading cause of maternal morbidity and mortality, yet women’s awareness during pregnancy and postpartum is not well characterized.</div></div><div><h3>Objectives</h3><div>To assess education and awareness of pregnancy-associated VTE across countries and healthcare systems, including sources of information, perceived understanding, and experiences with anticoagulation.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional online survey (15 languages), endorsed by the World Thrombosis Day campaign, of females who were pregnant or ≤12 months postpartum (October 2024 and September 2025). Descriptive analyses and subgroup comparisons were performed.</div></div><div><h3>Results</h3><div>Of 3043 responses, 3025 were analyzed. Overall, 69.8% reported no VTE education during pregnancy or the postpartum period, and 1.1% received education only at diagnosis, resulting in 70.9% with no or delayed VTE education. Upon delivery, comprehension was limited, with 36.2%, 46.8%, and 9.2% of females reporting full, partial, and poor understanding, respectively. Only 10.9% of females received instructions on VTE manifestations; among these, 16.3% were not advised to seek urgent care for suspected VTE events. Knowledge of pulmonary embolism-related signs was particularly poor. Prior VTE was reported in 13.3%, and 21.4% had ever used anticoagulants. Among participants who had discussed thromboprophylaxis and/or received anticoagulants, 32.4% were unaware of bleeding risks. Approximately 20% of those informed reported psychological distress related to VTE information. Education rates differed by age, education level, ethnicity, region, and reproductive factors.</div></div><div><h3>Conclusion</h3><div>VTE education during pregnancy and postpartum is infrequent and unevenly distributed. Enhanced educational interventions embedded within antenatal and postnatal care pathways are urgently needed to improve VTE awareness, symptom recognition, and informed decision-making.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"10 3","pages":"Article 103421"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147712451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic accuracy of Clauss and prothrombin time–derived fibrinogen against rotational thromboelastometry FIBTEM-A5","authors":"Akmez Latona ,&nbsp;Kate Hill ,&nbsp;Mark Rane ,&nbsp;Alan Ho ,&nbsp;Biswadev Mitra","doi":"10.1016/j.rpth.2026.103439","DOIUrl":"10.1016/j.rpth.2026.103439","url":null,"abstract":"<div><h3>Background</h3><div>Fibrinogen levels may fall early in major hemorrhage. The Clauss assay (Fib-C) is the laboratory gold standard, while the prothrombin time–derived assay (Fib-D) is a rapid, lower-cost alternative.</div></div><div><h3>Objectives</h3><div>To compare Fib-C and Fib-D with viscoelastic-derived clot firmness.</div></div><div><h3>Methods</h3><div>Data from all Queensland Health hospitals were extracted (2019-2025). Rotational Thromboelastometry FIBTEM-A5 was the reference standard. Paired Fib-C and Fib-D results with FIBTEM-A5 were analyzed. The primary outcome was correlation with FIBTEM-A5; secondary analyses assessed predictive performance for FIBTEM-A5 of ≤ 10 mm.</div></div><div><h3>Results</h3><div>Of 2208 paired results were included, Fib-C correlated more strongly with FIBTEM-A5 than Fib-D (<em>r</em> = 0.85 vs 0.82; <em>P</em> = .008) and had higher accuracy for FIBTEM-A5 of ≤ 10 mm (area under the curve, 0.92 vs 0.90; <em>P</em> &lt; .05). Optimal thresholds for FIBTEM-A5 of ≤ 10 mm were 2.1 g/L for Fib-C and 2.3g/L for Fib-D (<em>P</em> &lt; .05).For absolute fibrinogen values, Fib-D produced higher mean levels than Fib-C (overall, 2.3 vs 2.1 g/L; <em>P</em> &lt; .05), with differences observed in trauma (2.4 vs 2.2 g/L; <em>P</em> &lt; .05) and chronic liver disease (1.9 vs 1.7 g/L; <em>P</em> &lt; .05).</div></div><div><h3>Conclusion</h3><div>Fib-C aligns more closely with viscoelastic clot firmness than Fib-D. These results support Fib-C as the preferred assay and discontinuing routine Fib-D reporting in critical bleeding.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"10 3","pages":"Article 103439"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147712453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postpartum well-being in hemophilia carriers and women with von Willebrand disease: insights from patient-reported outcome measures","authors":"Anne de Vaan ,&nbsp;Elke A. Doeff ,&nbsp;Jeroen Eikenboom ,&nbsp;Marieke J.H.A. Kruip ,&nbsp;Marieke C. Punt ,&nbsp;Michiel Coppens ,&nbsp;Laurens Nieuwenhuizen ,&nbsp;Saskia E.M. Schols ,&nbsp;Anja B.U. Mäkelburg ,&nbsp;Floor C.J.I. Heubel-Moenen ,&nbsp;Hans J. Duvekot ,&nbsp;Marjolein Peters ,&nbsp;Annemieke Middeldorp ,&nbsp;Kitty W.M. Bloemenkamp ,&nbsp;Roger E.G. Schutgens ,&nbsp;Karin P.M. van Galen","doi":"10.1016/j.rpth.2026.103418","DOIUrl":"10.1016/j.rpth.2026.103418","url":null,"abstract":"<div><h3>Background</h3><div>Hemophilia carriers (HCs) and women with von Willebrand disease (VWD) receive specialized obstetric care because of a higher chance for postpartum bleeding and potential bleeding in the neonates. It is unknown what their postpartum quality of life (QoL), childbirth satisfaction, and experience are and how this differs from the general population.</div></div><div><h3>Objectives</h3><div>This study assessed QoL, childbirth satisfaction and experience in HCs and women with VWD at week 1 and 6 postpartum. These outcomes are compared with those from retrospective studies of the general population.</div></div><div><h3>Methods</h3><div>Participants completed 3 patient-reported outcome measures postpartum: the Short Form-36 at week 1 and 6 measuring QoL, the Mackey Childbirth Satisfaction Rate Scale at week 1 for childbirth satisfaction, and the Labor and Delivery Index at week 6 for childbirth experience. Descriptive statistics were used.</div></div><div><h3>Results</h3><div>In total, 85 HCs and 81 women with VWD completed ≥1 questionnaire. Pain and physical functioning improved over time (both moderate to fairly well; <em>P</em> &lt; .001). Six weeks postpartum, QoL was lower in both groups than those in the general population. Over 88% of both cohorts reported “at least satisfied” on the Mackey Childbirth Satisfaction Rate Scale, significantly higher than the general population (&gt;61%; <em>P</em> &lt; .001). Mean Labor and Delivery Index scores (1.3-1.9 points) indicated an adequate childbirth experience. HCs reported more child-related worries than the general population (37.3% vs 72.2%; <em>P</em> &lt; .001).</div></div><div><h3>Conclusion</h3><div>HCs and women with VWD recover less between week 1 and 6 postpartum than the general population. HCs report more worries about their child during childbirth than women with VWD and the general population.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"10 3","pages":"Article 103418"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147712876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative phenotyping of surface markers and glycans in murine and human platelet-derived extracellular vesicles","authors":"Olga An ,&nbsp;Friedrich Reusswig ,&nbsp;Viola Krenzlin ,&nbsp;Carsten Deppermann ,&nbsp;Dianne E. van der Wal","doi":"10.1016/j.rpth.2026.103414","DOIUrl":"10.1016/j.rpth.2026.103414","url":null,"abstract":"<div><h3>Background</h3><div>Platelet-derived extracellular vesicles (PEVs, 100-1000 nm in size) are released from activated platelets. They are important carriers of signaling molecules, lipids, and proteins. They interact with immune and tumor cells and, thus, hold great promise as drug delivery tools. They express a plethora of unique surface glycans, and the majority of PEVs in circulation are nonprocoagulant and phosphatidylserine-negative. Despite an increasing number of studies on PEVs, receptor and glycosylation profiles of murine and human PEVs have not been characterized systematically.</div></div><div><h3>Objectives</h3><div>To characterize large PEVs (l-PEVs) generated from human and murine platelets using double stimulation of glycoprotein VI (GPVI) and PAR1/4 pathways, as well as ionophore A23187.</div></div><div><h3>Methods</h3><div>Surface glycoprotein and glycosylation profiles of human and mouse l-PEVs were determined using flow cytometry, western blotting, and lectin array.</div></div><div><h3>Results</h3><div>Interestingly, murine samples showed a significantly altered glycoprotein expression and glycosylation compared with human l-PEVs. Following stimulation, GPVI, CD41/CD61, and CD62P were expressed to a lower extent on murine l-PEVs. CD42b (GPIb) was not highly abundant on l-PEVs from both species. The pan-inhibition of metalloproteinases resulted in recovery of CD42b but not GPVI on l-PEVs. Moreover, the analysis of surface and the total content of carbohydrates of the l-PEVs showed species-specific surface glycan exposure. We also detected only minor differences in phenotypes of l-PEVs generated from buffy coat or fresh blood and between l-PEVs generated from blood with different types of anticoagulation.</div></div><div><h3>Conclusion</h3><div>We identified specific differences in the phenotype of mouse vs human l-PEVs, which contribute to our understanding on the role of PEVs, which should be considered when designing future PEV studies, for example, in commonly used murine models of disease.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"10 3","pages":"Article 103414"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147636445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}